Is This Dividend Stock Worth Your Time?

ZMH Dividend Chart
ZMH Dividend Chart

ZMH Dividend data by YCharts

Now it's time to answer our initial question: Is this healthcare dividend stock worth your time?

Based on its current outlook and yield I'm going to take what I suspect will be an unpopular opinion and say "No."

My reasoning rests primarily with the high level of competition in the orthopedic space. Zimmer's annual gross margin has been on a general downward trend since 2006, from 77.7% to just 72.4% last year. And operating margin has declined from 33.4% to 28.3% over the same period. There is the possibility that Biomet could help reverse this downtrend, but the integration of these two behemoths is going to take time. Translation: margin improvement likely won't be apparent until 2016 at the earliest in my opinion.

Also, Zimmer's payout ratio leaves a lot to be desired. It's perhaps a bit understandable why the company kept its payouts so low if it was eyeing an acquisition all along, but there are a handful of other medical device names that investors can consider which offer far more attractive organic growth rates and pay out a larger percentage of their earnings on an annual basis.

You could certainly do a lot worse than Zimmer, but as a dividend stock I'd give this one a pass.

If you're looking for high-yield dividend stocks, look no further than these companies handpicked by our top analysts!

The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now .

The article Is This Dividend Stock Worth Your Time? originally appeared on

Sean Williamshas no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, track every pick he makes under the screen nameTrackUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.The Motley Fool owns shares of, and recommends Johnson & Johnson. It also owns shares of Zimmer Holdings. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More